Anti-Fibrinolytic Drugs - GCC | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in GCC is expected to witness a significant increase in revenue, projected to reach US$150.20m by 2024.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 4.79%, leading to a market volume of US$189.80m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the market, with an estimated value of US$9.86bn in 2024.
The GCC market for Anti-Fibrinolytic Drugs is witnessing a surge in demand due to an aging population and an increase in surgical procedures.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The demand for Anti-Fibrinolytic Drugs in the GCC region has been on the rise in recent years.

Customer preferences: The Anti-Fibrinolytic Drugs market in the GCC region is primarily driven by the demand for these drugs in the treatment of bleeding disorders. The market is also influenced by the increasing number of surgeries being performed in the region, particularly in countries such as Saudi Arabia and the UAE.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in the GCC region is the increasing use of these drugs in the treatment of trauma patients. With the rising number of road accidents in the region, trauma cases have become more common. This has led to an increased demand for Anti-Fibrinolytic Drugs, which can help control bleeding in trauma patients.Another trend in the market is the growing popularity of topical Anti-Fibrinolytic Drugs. These drugs are applied directly to the site of bleeding, and are particularly useful in surgeries where the bleeding is localized. Topical Anti-Fibrinolytic Drugs are becoming increasingly popular in the GCC region due to their ease of use and effectiveness.

Local special circumstances: The Anti-Fibrinolytic Drugs market in the GCC region is heavily influenced by the region's healthcare infrastructure. Countries such as Saudi Arabia and the UAE have invested heavily in their healthcare systems in recent years, which has led to an increased demand for medical products, including Anti-Fibrinolytic Drugs. Another important factor is the region's demographics. The GCC region has a young and growing population, which has led to an increased demand for healthcare services. This trend is expected to continue in the coming years, which bodes well for the Anti-Fibrinolytic Drugs market.

Underlying macroeconomic factors: The GCC region is home to some of the world's largest oil reserves, which has led to significant economic growth in recent years. This growth has led to an increase in disposable income, which has in turn led to an increased demand for healthcare services, including Anti-Fibrinolytic Drugs.Another important macroeconomic factor is the region's focus on medical tourism. Countries such as the UAE have invested heavily in their healthcare infrastructure in order to attract medical tourists from around the world. This has led to an increased demand for medical products, including Anti-Fibrinolytic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.